Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis

2014613 citationsJournal Articlebronze Open Access

Authors

Harry R. Büller · Academic Medical Center

Claudette Bethune · Ionis Pharmaceuticals (United States)

Sanjay Bhanot · Ionis Pharmaceuticals (United States)

David Gailani · Vanderbilt University

Brett P. Monia · Ionis Pharmaceuticals (United States)

Gary E. Raskob · University of Oklahoma Health Sciences Center

Annelise Segers

Abstract

This study showed that factor XI contributes to postoperative venous thromboembolism; reducing factor XI levels in patients undergoing elective primary unilateral total knee arthroplasty was an effective method for its prevention and appeared to be safe with respect to the risk of bleeding. (Funded by Isis Pharmaceuticals; FXI-ASO TKA ClinicalTrials.gov number, NCT01713361.).

Topics & Keywords

Coagulation, Bradykinin, Polyphosphates, and Angioedema Blood Coagulation and Thrombosis Mechanisms Mast cells and histamine

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 372, Issue 3, pp. 232-240

DOI: 10.1056/nejmoa1405760

Field-Weighted Citation Impact: 27.84